Voices
Daisuke Kotani: ASCO Guideline Update on Immunotherapy and Targeted Therapy in GEC
Daisuke Kotani/X

Daisuke Kotani: ASCO Guideline Update on Immunotherapy and Targeted Therapy in GEC

Daisuke Kotani, GI Medical Oncologist, Chief Physician at the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East, Japan, shared a post on X:

“Immunotherapy and Targeted Therapy for Gastroesophageal Cancer: ASCO Guideline Update

Adenocarcinoma

HER2-postive

  • CPS ≥1: Pembro + Trastuzumab + Chemo
  • CPS <1: Tras + Chemo

HER2-negative

  • CPS ≥1 and CLDN(-): ICI + Chemo
  • CPS <1 and CLDN(+): Zolbe + Chemo
  • CPS ≥1 and CLDN(+): ICI or Zolbe + Chemo
  • CPS <1 and CLDN(-): Chemo alone

SCC

  • CPS ≥1: ICI + Chemo or Nivo + Ipi
  • CPS <1: Chemo alone

Visualizing estimated rate of death per 1,000 patients with GEA by CPS(see photo in the Gallery).”

Title: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update

Authors: Manish Shah, Erin Kennedy, Dana Deighton, Minaxi Jhawer, Kunal Kadakia, Sarbajit Mukherjee, Christopher Nevala-Plagemann, Anwaar Saeed, Bryan Schneider, Thomas Semrad, Kohei Shitara, Laura Tenner, Nataliya Uboha, Melani Vincelli, Davit Zohrabyan, Lakshmi Rajdev

Read the Full Article.

Daisuke Kotani: ASCO Guideline Update on Immunotherapy and Targeted Therapy in GEC

Other articles about Daisuke Kotani on OncoDaily.

Anwaar Saeed ASCO Bryan Schneider cancer Christopher Nevala-Plagemann Daisuke Kotani Dana Deighton Davit Zohrabyan Erin Kennedy Kohei shitara Kunal Kadakia Lakshmi Rajdev Laura Tenner Manish Shah Melani Vincelli Minaxi Jhawer Nataliya Uboha OncoDaily Oncology Sarbajit Mukherjee Thomas Semrad